{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:21:12Z","timestamp":1766067672728,"version":"3.28.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":134,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.nefroe.2021.04.012","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:42:55Z","timestamp":1675348975000},"page":"594-606","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study"],"prefix":"10.1016","volume":"42","author":[{"given":"Mar\u00eda Auxiliadora","family":"Bajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"R\u00edos-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Dolores","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n Jes\u00fas","family":"Devesa-Such","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Molina-Higueras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Martin-Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Peir\u00f3-Jord\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cannata-Andia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel Luis","family":"Mart\u00edn-De Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.nefroe.2021.04.012_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.nefroe.2021.04.012_bib0010","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/14656566.2018.1491548","article-title":"Sucroferric oxyhydroxide for the treatment of hyperphosphatemia","volume":"19","author":"Sprague","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.nefroe.2021.04.012_bib0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"SUPPL. 2","key":"10.1016\/j.nefroe.2021.04.012_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.reuma.2011.05.006","article-title":"Trastorno mineral y \u00f3seo asociado a la enfermedad renal cr\u00f3nica","volume":"7","author":"Arboleya","year":"2011","journal-title":"Reumatol Clin"},{"issue":"1","key":"10.1016\/j.nefroe.2021.04.012_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO)CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"Suppl. 1","key":"10.1016\/j.nefroe.2021.04.012_bib0030","first-page":"3","article-title":"Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic kidney disease patients (S.E.N.-M.B.D)","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrologia"},{"issue":"9","key":"10.1016\/j.nefroe.2021.04.012_bib0035","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study","volume":"30","author":"Fernandez-Martin","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.nefroe.2021.04.012_bib0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrneph.2011.112","article-title":"Pharmacology, efficacy and safety of oral phosphate binders","volume":"7","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.nefroe.2021.04.012_bib0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.nefro.2018.05.003","article-title":"Pharmacological interactions of phosphate binders","volume":"38","author":"Bover Sanju\u00e1n","year":"2018","journal-title":"Nefrologia"},{"issue":"17","key":"10.1016\/j.nefroe.2021.04.012_bib0050","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1517\/14656566.2011.626768","article-title":"Pharmacotherapy of chronic kidney disease and mineral bone disorder","volume":"12","author":"Barreto","year":"2011","journal-title":"Expert Opin Pharmacother."},{"issue":"7","key":"10.1016\/j.nefroe.2021.04.012_bib0055","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/ndt\/gfs418","article-title":"COSMOS: the dialysis scenario of CKD-MBD in Europe","volume":"28","author":"Fern\u00e1ndez-Mart\u00edn","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.nefroe.2021.04.012_bib0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","article-title":"The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro","volume":"81","author":"Wilhelm","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2021.04.012_bib0065","unstructured":"VELPHORO (sucroferric oxyhydroxide). Highlights of prescribing information (available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205109s006lbl.pdf. Accedido Febrero 2019."},{"key":"10.1016\/j.nefroe.2021.04.012_bib0070","unstructured":"VELPHORO (sucroferric oxyhydroxide). Summary of Product Characteristics (available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/velphoro-epar-product-information_en.pdf). Accedido Febrero 2019."},{"issue":"3","key":"10.1016\/j.nefroe.2021.04.012_bib0075","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nefroe.2021.04.012_bib0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.nefroe.2021.04.012_bib0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487856","article-title":"Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide","volume":"47","author":"Kalantar-Zadeh","year":"2018","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.nefroe.2021.04.012_bib0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CN109021","article-title":"Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data","volume":"88","author":"Coyne","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2021.04.012_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJNRD.S182747","article-title":"Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide","volume":"12","author":"Gray","year":"2019","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"4","key":"10.1016\/j.nefroe.2021.04.012_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.jrn.2016.01.009","article-title":"An update on phosphate binders: a dietitian\u2019s perspective","volume":"26","author":"Gutekunst","year":"2016","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.nefroe.2021.04.012_bib0105","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ckj\/sfaa211","article-title":"Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study","volume":"14","author":"Vervloet","year":"2021","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.nefroe.2021.04.012_bib0110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/j.ajkd.2018.04.019","article-title":"Missed hemodialysis treatments: international variation, predictors, and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"72","author":"Al Salmi","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.nefroe.2021.04.012_bib0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"W\u00fcthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.nefroe.2021.04.012_bib0120","first-page":"1363","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.nefroe.2021.04.012_bib0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology"},{"issue":"1","key":"10.1016\/j.nefroe.2021.04.012_bib0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"issue":"6","key":"10.1016\/j.nefroe.2021.04.012_bib0135","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nefroe.2021.04.012_bib0140","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.nefro.2020.04.011","article-title":"How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide","volume":"40","author":"Arenas Jim\u00e9nez","year":"2020","journal-title":"Nefrolog\u00eda"},{"issue":"5","key":"10.1016\/j.nefroe.2021.04.012_bib0145","first-page":"522","article-title":"Captores del f\u00f3sforo: preferencias de los pacientes en hemodi\u00e1lisis y su repercusi\u00f3n sobre el cumplimiento del tratamiento y el control del f\u00f3sforo","volume":"30","author":"Arenas","year":"2010","journal-title":"Nefrologia"},{"issue":"1","key":"10.1016\/j.nefroe.2021.04.012_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN109054","article-title":"A strategy based on patient preference improves the adherence and outcomes of phosphate binders in hemodialysis","volume":"88","author":"Jim\u00e9nez","year":"2017","journal-title":"Clin Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T17:16:46Z","timestamp":1730049406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2013251423000160"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.04.012","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2021.04.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}